The IND clearance and cash raise remove near-term bankruptcy risk, but the massive dilution and Nasdaq delisting overhang (MVLS ~$3.4M vs $5M threshold) cap upside. Monitor Phase II enrollment updates and DeepSolar commercial traction for catalyst timing. The June SEPA allows further dilution at the company's discretion — any drawdowns will pressure the stock.
Price Chart
Executive Summary
PRF Technologies (PRFX) reported H1 2026 results showing a net loss of $2.8M (up from $2.3M) but generated first-ever revenue of $14k from DeepSolar. The FDA cleared the IND for OcuRing-K, enabling a Phase II cataract surgery trial with enrollment expected H2 2026. Cash nearly tripled to $11.6M following a $10M SEPA drawdown, but shares outstanding surged from 830k to 3.04M. The company faces Nasdaq delisting risk with MVLS at ~$3.4M vs the $5M threshold under a new rule currently under SEC stay.
Key Facts
- FDA cleared IND for OcuRing-K, enabling multi-center Phase II trial in cataract surgery with patient enrollment expected H2 2026
- PRF-110 demonstrated 72-hour analgesic activity comparable to ZYNRELEF in a head-to-head porcine study using NSAID-free formulation
- Cash, short-term deposits and restricted cash nearly tripled to $11.6M at June 30, 2026 from $4.2M at Dec 31, 2025
- Raised $10.0M gross via May 2026 SEPA (fully utilized, 2,152,798 shares issued); entered $15.0M June 2026 SEPA with $447k drawn post-period
- Net loss attributable to shareholders widened to $2.8M for H1 2026 vs $2.3M for H1 2025
- G&A expenses decreased 39% YoY to $1.2M; R&D nearly tripled to $0.8M driven by solar segment and LayerBio
- First revenue of $14k from DeepSolar commercial engagements (SaaS with Shikun & Binui Energy, due diligence with EDF Power Solutions Israel)
- Shares outstanding increased from 830,613 to 3,041,830 in H1 2026 due to SEPA issuances and reverse split adjustment
- MVLS was ~$3.4M as of Sep 2, 2026, below the $5.0M threshold under new Nasdaq rule currently stayed by SEC pending review
- Accumulated deficit reached $64.1M; auditor issued going concern warning in prior 20-F
Financial Impact
Cash position improved by $7.4M to $11.6M, but net loss increased $0.5M to $2.8M and share count quadrupled, creating significant dilution for existing holders.
Risk Factors
- Nasdaq delisting risk: MVLS of ~$3.4M is below $5M threshold; if SEC stay is lifted, trading could be suspended immediately with no cure period
- Massive dilution: shares outstanding grew 3.7x in H1 2026; $15M June SEPA remains undrawn and can be tapped at any time at 97% of VWAP
- Going concern: accumulated deficit of $64.1M, history of losses, and dependence on future capital raises
- Clinical risk: OcuRing-K Phase II has not yet enrolled; PRF-110 requires additional trials before any potential approval
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004401 |
| Exhibit: exhibit_99-2.htm | 0001178913-26-004401 |
| Exhibit: exhibit_99-3.htm | 0001178913-26-004401 |
| Document: zk2635991.htm | 0001178913-26-004401 |
| Document: 0001178913-26-004401-index-headers.html | 0001178913-26-004401 |
| Document: 0001178913-26-004401-index.html | 0001178913-26-004401 |
| Document: 0001178913-26-004401.txt | 0001178913-26-004401 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 6-K | $0.7252 | awaiting T+60 | — | $0.7251 (−0.01%) |
Oct 23, 2026 3d ago | Press Release | $0.7108 | awaiting T+60 | — | $0.7251 (+2.01%) |
Sep 28, 2026 28d ago | 6-K | $0.9720 | awaiting T+60 | — | $0.7251 (−25.40%) |
Sep 24, 2026 4w ago | SC 13D | $0.9767 | awaiting T+60 | — | $0.7251 (−25.76%) |
Sep 16, 2026 5w ago | 6-K | $1.01 | awaiting T+60 | — | $0.7251 (−28.21%) |
Sep 4, 2026 7w ago | EFFECT | $0.9680 | awaiting T+60 | — | $0.7251 (+25.09%) |
Sep 3, 2026 7w ago | 6-K | $0.9792 | awaiting T+60 | — | $0.7251 (−25.95%) |
Sep 3, 2026 7w ago | Press Release | $0.9792 | awaiting T+60 | — | $0.7251 (−25.95%) |
Jul 27, 2026 13w ago | 6-K | $1.09 $0.7120 | ▼ −34.68% | ▼ −38.38% | $0.7251 (−33.48%) |
Jul 21, 2026 13w ago | 6-K | $1.20 $0.8180 | ▼ −31.83% | ▼ −35.81% | $0.7251 (−39.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers